FI931203A0 - Karboxylsyraestrar av rapamycin - Google Patents

Karboxylsyraestrar av rapamycin

Info

Publication number
FI931203A0
FI931203A0 FI931203A FI931203A FI931203A0 FI 931203 A0 FI931203 A0 FI 931203A0 FI 931203 A FI931203 A FI 931203A FI 931203 A FI931203 A FI 931203A FI 931203 A0 FI931203 A0 FI 931203A0
Authority
FI
Finland
Prior art keywords
carboxylsyraestrar
rapamycin
Prior art date
Application number
FI931203A
Other languages
English (en)
Other versions
FI931203A (fi
Inventor
Craig Eugene Caufield
Amedeo Arturo Failli
Robert John Steffan
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/657,294 external-priority patent/US5130307A/en
Application filed by American Home Prod filed Critical American Home Prod
Publication of FI931203A publication Critical patent/FI931203A/fi
Publication of FI931203A0 publication Critical patent/FI931203A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FI931203A 1990-09-19 1993-03-18 Karboxylsyraestrar av rapamycin FI931203A0 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58483390A 1990-09-19 1990-09-19
US58987890A 1990-09-28 1990-09-28
US07/657,294 US5130307A (en) 1990-09-28 1991-02-19 Aminoesters of rapamycin
PCT/US1991/006824 WO1992005179A1 (en) 1990-09-19 1991-09-19 Carboxylic acid esters of rapamycin

Publications (2)

Publication Number Publication Date
FI931203A FI931203A (fi) 1993-03-18
FI931203A0 true FI931203A0 (fi) 1993-03-18

Family

ID=27416444

Family Applications (1)

Application Number Title Priority Date Filing Date
FI931203A FI931203A0 (fi) 1990-09-19 1993-03-18 Karboxylsyraestrar av rapamycin

Country Status (9)

Country Link
EP (1) EP0549727A1 (fi)
JP (1) JPH06501012A (fi)
AU (1) AU653175B2 (fi)
FI (1) FI931203A0 (fi)
HU (1) HUT65763A (fi)
IE (1) IE913302A1 (fi)
MX (1) MX9101139A (fi)
PT (1) PT98990A (fi)
WO (1) WO1992005179A1 (fi)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0427680T3 (da) * 1989-11-09 1995-12-18 Sandoz Ltd Heteroatom-holdige cykliske forbindelser
FI921595A (fi) * 1991-04-17 1992-10-18 American Home Prod Rapamycinkarbamater
US5565560A (en) * 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5262533A (en) * 1991-05-13 1993-11-16 Merck & Co., Inc. Amino O-aryl macrolides having immunosuppressive activity
US5247076A (en) * 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
US5284877A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkyl and alkenyl macrolides having immunosuppressive activity
US5284840A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkylidene macrolides having immunosuppressive activity
ATE321053T1 (de) * 1992-10-13 2006-04-15 Wyeth Corp Carbamate von rapamycin
US5262423A (en) * 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5310901A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives
US5310903A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. Imidazolidyl rapamycin derivatives
GB9307491D0 (en) 1993-04-08 1993-06-02 Sandoz Ltd Organic compounds
USRE40596E1 (en) * 1993-04-08 2008-12-02 Novartis Ag Rapamycin assay
US5504091A (en) * 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US7279561B1 (en) 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
ES2176245T3 (es) 1993-04-23 2002-12-01 Wyeth Corp Anticuerpos de ramapicinas de ciclo abierto.
AU6711994A (en) * 1993-04-23 1994-11-21 American Home Products Corporation Rapamycin conjugates and antibodies
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
CA2175215C (en) * 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
SG64372A1 (en) * 1993-12-17 1999-04-27 Novartis Ag Rapamycin derivatives
US5389639A (en) * 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5693648A (en) * 1994-09-30 1997-12-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
PE52896A1 (es) 1994-10-26 1996-12-12 Novartis Ag Composicion farmaceutica
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
WO1996041807A1 (en) * 1995-06-09 1996-12-27 Novartis Ag Rapamycin derivatives
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US20030129215A1 (en) 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US7357942B2 (en) 1997-09-26 2008-04-15 Abbott Laboratories Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
US8057816B2 (en) 1997-09-26 2011-11-15 Abbott Laboratories Compositions and methods of administering paclitaxel with other drugs using medical devices
US8394398B2 (en) 1997-09-26 2013-03-12 Abbott Laboratories Methods of administering rapamycin analogs with anti-inflammatories using medical devices
US7378105B2 (en) 1997-09-26 2008-05-27 Abbott Laboratories Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens
US8257725B2 (en) 1997-09-26 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US8257726B2 (en) 1997-09-26 2012-09-04 Abbott Laboratories Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
US7455853B2 (en) 1998-09-24 2008-11-25 Abbott Cardiovascular Systems Inc. Medical devices containing rapamycin analogs
US7960405B2 (en) 1998-09-24 2011-06-14 Abbott Laboratories Compounds and methods for treatment and prevention of diseases
US8257724B2 (en) 1998-09-24 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
ES2377847T3 (es) 1999-01-13 2012-04-02 Bayer Healthcare Llc Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1210350B1 (en) * 1999-08-18 2004-07-14 Wyeth Water soluble sdz-rad esters
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
GB0008785D0 (en) 2000-04-10 2000-05-31 Novartis Ag Organic compounds
EP1319008B1 (en) * 2000-09-19 2008-10-15 Wyeth Water soluble rapamycin esters
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
PL375698A1 (en) 2002-09-06 2005-12-12 Abbott Laboratories Medical device having hydration inhibitor
WO2004060283A2 (en) 2002-12-16 2004-07-22 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US7160867B2 (en) * 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
DK1626714T3 (da) 2003-05-20 2007-10-15 Bayer Pharmaceuticals Corp Dirarylurinstoffer mod sygdomme medieret af PDGFR
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US8431145B2 (en) 2004-03-19 2013-04-30 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
US7445916B2 (en) 2004-04-14 2008-11-04 Wyeth Process for preparing rapamycin 42-esters and FK-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
US7268144B2 (en) * 2004-04-14 2007-09-11 Wyeth Regiospecific synthesis of rapamycin 42-ester derivatives
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
DK1848431T3 (en) 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
WO2006096325A1 (en) 2005-03-07 2006-09-14 Wyeth Oxepane isomer of 42-o-(2-hydroxy)ethyl-rapamycin
EP3138531A1 (en) 2005-03-23 2017-03-08 Abbott Laboratories Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
JP5271697B2 (ja) 2005-03-23 2013-08-21 アボット ラボラトリーズ 医療装置を介する高親油性薬剤の送達
US20080200486A1 (en) 2005-07-20 2008-08-21 Heidi Lane Combination Of Organic Compounds
EP1956906A4 (en) 2005-11-09 2009-12-30 Combinatorx Inc METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES
WO2007059311A2 (en) 2005-11-16 2007-05-24 Nitromed, Inc. Furoxan compounds, compositions and methods of use
JP2009516671A (ja) 2005-11-21 2009-04-23 ノバルティス アクチエンゲゼルシャフト ｍＴＯＲ阻害剤を使用する神経内分泌腫瘍処置
US7700614B2 (en) 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
AU2007212271B2 (en) 2006-02-09 2012-11-01 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
US20070203169A1 (en) * 2006-02-28 2007-08-30 Zhao Jonathon Z Isomers and 42-epimers of rapamycin ester analogs, methods of making and using the same
US7622477B2 (en) 2006-02-28 2009-11-24 Cordis Corporation Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
US7678901B2 (en) 2006-02-28 2010-03-16 Wyeth Rapamycin analogs containing an antioxidant moiety
BRPI0709016A2 (pt) 2006-03-23 2011-06-21 Macusight Inc formulações e métodos para doenças ou condições relacionadas com a permeabilidade vascular
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
EP2077819A4 (en) 2006-09-28 2011-05-25 Follica Inc METHODS, MATERIALS, AND COMPOSITIONS FOR GENERATING NEW CELLULAR FOLLICLES AND PUSHING HAIR
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
BRPI0722361B8 (pt) 2007-12-19 2021-07-27 Abbott Lab métodos para avaliar a concentração de um fármaco imunossupressor em uma amostra de sangue humano, composição de reagente de extração e kit de teste
US8921642B2 (en) 2008-01-11 2014-12-30 Massachusetts Eye And Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
EP3023433A1 (en) 2009-02-05 2016-05-25 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
EP2470179B1 (en) 2009-08-26 2017-11-29 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Sustained release delivery systems for the prevention and treatment of head and neck cancers
US8951595B2 (en) 2009-12-11 2015-02-10 Abbott Cardiovascular Systems Inc. Coatings with tunable molecular architecture for drug-coated balloon
CA2800327A1 (en) 2010-04-13 2011-10-20 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
CN102834094B (zh) 2010-04-16 2015-05-06 诺华有限公司 有机化合物的组合产品及其制药用途
KR101253399B1 (ko) 2010-10-26 2013-04-11 영남대학교 산학협력단 아포지단백질 ａ－ｉ 및 그 변이체를 포함한 재조합 고밀도지단백질을 이용한 라파마이신 제형
CA2852056C (en) 2011-03-11 2021-08-10 Beth Israel Deaconess Medical Center, Inc. Anti-cd40 antibodies and uses thereof
KR101925656B1 (ko) 2011-04-25 2018-12-05 노파르티스 아게 포스파티딜이노시톨-3-키나제 (pi3k) 억제제 및 mtor 억제제의 조합물
NZ631340A (en) 2012-03-23 2016-11-25 Univ Queensland Immunomodulatory agent and uses therefor
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
WO2013192367A1 (en) 2012-06-22 2013-12-27 Novartis Ag Neuroendocrine tumor treatment
EP2919759A4 (en) 2012-11-14 2016-07-20 Ohio State Innovation Foundation MATERIALS AND METHODS FOR THE TREATMENT OF GLIOBLASTOMES
CA2904170A1 (en) 2013-03-14 2014-09-25 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
WO2014165679A1 (en) 2013-04-03 2014-10-09 Allertein Therapeutics, Llc Novel nanoparticle compositions
WO2014184734A1 (en) 2013-05-14 2014-11-20 Novartis Ag Markers associated with mtor inhibition
KR20160058774A (ko) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
WO2015044854A1 (en) 2013-09-24 2015-04-02 Novartis Ag Markers associated with mtor inhibition
JP2017505345A (ja) 2014-02-11 2017-02-16 ノバルティス アーゲー がんの処置のためのｐｉ３ｋ阻害剤を含む組合せ医薬
WO2015149001A1 (en) 2014-03-27 2015-10-01 The Brigham And Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
US10258639B2 (en) 2014-05-06 2019-04-16 Research Development Foundation Methods for treating insulin resistance and for sensitizing patients to GLP1 agonist therapy
CN105461738B (zh) * 2014-06-03 2019-03-08 中国人民解放军军事医学科学院毒物药物研究所 一种雷帕霉素衍生物、其制备方法、其药物组合物及用途
CN107073066B (zh) 2014-09-11 2021-09-17 加利福尼亚大学董事会 mTORC1抑制剂
AU2016315873B2 (en) 2015-09-04 2022-08-18 Primatope Therapeutics Inc. Humanized anti-CD40 antibodies and uses thereof
US20190290631A1 (en) 2016-05-27 2019-09-26 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof
BR112018077259A2 (pt) 2016-06-30 2019-06-18 Durect Corporation formulações depot
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
MX2019007643A (es) 2016-12-22 2019-09-09 Amgen Inc Benzoisotiazol, isotiazolo[3,4-b]piridina, quinazolina, ftalazina, pirido[2,3-d]piridazina y derivados de pirido[2,3-d]pirimidina como inhibirores de kras g12c para tratar el cancer de pulmon, pancreatico o colorrectal.
EA201990127A1 (ru) 2016-12-30 2020-08-18 Дьюрект Корпорейшн Депо-препарат
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
EP4403175A3 (en) 2017-09-08 2024-10-02 Amgen Inc. Inhibitors of kras g12c and methods of using the same
LT3788049T (lt) 2018-05-01 2023-07-25 Revolution Medicines, Inc. Rapamicino analogai, sujungti su c40-, c28- ir c32-, kaip mtor inhibitoriai
IL312291A (en) 2018-05-01 2024-06-01 Revolution Medicines Inc C-26-linked rapamycin analogs as MTOR inhibitors
AU2019262599B2 (en) 2018-05-04 2023-10-12 Amgen Inc. KRAS G12C inhibitors and methods of using the same
WO2019213516A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
EP3790886B1 (en) 2018-05-10 2024-06-26 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
AU2019278998B2 (en) 2018-06-01 2023-11-09 Amgen Inc. KRAS G12C inhibitors and methods of using the same
CA3099799A1 (en) 2018-06-11 2019-12-19 Amgen Inc. Kras g12c inhibitors for treating cancer
US11285156B2 (en) 2018-06-12 2022-03-29 Amgen Inc. Substituted piperazines as KRAS G12C inhibitors
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
US11053226B2 (en) 2018-11-19 2021-07-06 Amgen Inc. KRAS G12C inhibitors and methods of using the same
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
MA54543A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
WO2020132651A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
CA3123227A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
MX2021007157A (es) 2018-12-20 2021-08-16 Amgen Inc Heteroarilamidas utiles como inhibidores de kif18a.
AU2020232616A1 (en) 2019-03-01 2021-09-09 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
CN113767100A (zh) 2019-03-01 2021-12-07 锐新医药公司 双环杂芳基化合物及其用途
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
KR20220011670A (ko) 2019-05-21 2022-01-28 암젠 인크 고체 상태 형태
US20220281843A1 (en) 2019-08-02 2022-09-08 Amgen Inc. Kif18a inhibitors
US20220372018A1 (en) 2019-08-02 2022-11-24 Amgen Inc. Kif18a inhibitors
AU2020326627A1 (en) 2019-08-02 2022-03-17 Amgen Inc. KIF18A inhibitors
US20240254100A1 (en) 2019-08-02 2024-08-01 Amgen Inc. Kif18a inhibitors
WO2021055728A1 (en) 2019-09-18 2021-03-25 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
JP2022552873A (ja) 2019-10-24 2022-12-20 アムジエン・インコーポレーテツド がんの治療におけるｋｒａｓ ｇ１２ｃ及びｋｒａｓ ｇ１２ｄ阻害剤として有用なピリドピリミジン誘導体
IL292438A (en) 2019-10-28 2022-06-01 Merck Sharp & Dohme Small molecules that inhibit the g12c mutant of kras
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
AU2020379734A1 (en) 2019-11-04 2022-05-05 Revolution Medicines, Inc. Ras inhibitors
TW202132314A (zh) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ｒａｓ抑制劑
US11739074B2 (en) 2019-11-04 2023-08-29 Revolution Medicines, Inc. Ras inhibitors
JP2023500328A (ja) 2019-11-08 2023-01-05 レボリューション メディシンズ インコーポレイテッド 二環式ヘテロアリール化合物及びその使用
AR120456A1 (es) 2019-11-14 2022-02-16 Amgen Inc Síntesis mejorada del compuesto inhibidor de g12c de kras
US20230192681A1 (en) 2019-11-14 2023-06-22 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
CN118767143A (zh) 2019-12-12 2024-10-15 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
JP2023509701A (ja) 2020-01-07 2023-03-09 レヴォリューション・メディスンズ，インコーポレイテッド Ｓｈｐ２阻害剤投薬およびがんを処置する方法
US20230181536A1 (en) 2020-04-24 2023-06-15 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
US20230174518A1 (en) 2020-04-24 2023-06-08 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
JP7373664B2 (ja) 2020-07-15 2023-11-02 大鵬薬品工業株式会社 腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ
WO2022060583A1 (en) 2020-09-03 2022-03-24 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
AU2021345111A1 (en) 2020-09-15 2023-04-06 Revolution Medicines, Inc. Indole derivatives as Ras inhibitors in the treatment of cancer
AU2021409816A1 (en) 2020-12-22 2023-07-06 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
WO2022235864A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
CN117616031A (zh) 2021-05-05 2024-02-27 锐新医药公司 用于治疗癌症的ras抑制剂
WO2022250170A1 (en) 2021-05-28 2022-12-01 Taiho Pharmaceutical Co., Ltd. Small molecule inhibitors of kras mutated proteins
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024081916A1 (en) 2022-10-14 2024-04-18 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316885A (en) * 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
JP3140228B2 (ja) * 1992-02-17 2001-03-05 ファイザー製薬株式会社 新規な大環状ラクトンおよびその生産菌

Also Published As

Publication number Publication date
EP0549727A1 (en) 1993-07-07
AU8659991A (en) 1992-04-15
WO1992005179A1 (en) 1992-04-02
IE913302A1 (en) 1992-02-25
JPH06501012A (ja) 1994-01-27
AU653175B2 (en) 1994-09-22
HUT65763A (en) 1994-07-28
FI931203A (fi) 1993-03-18
HU9300776D0 (en) 1993-06-28
PT98990A (pt) 1992-08-31
MX9101139A (es) 1992-05-04

Similar Documents

Publication Publication Date Title
FI931203A (fi) Karboxylsyraestrar av rapamycin
FI921328A (fi) Silyletrar av rapamycin
FI930886A0 (fi) Foerfarande foer hindrande av avstoetning av transplanterad vaevnad
FI932336A0 (fi) Inhibering av celladhesionprotein-kolhydratvaexelverkan
FI930848A0 (fi) Foerfarande foer separering av ilmenit
FI923931A (fi) Anordning foer granskning av insidan av en foergrenad roerlinje
FI931357A (fi) Framstaellning av polyhydroxifettsyraamider i naervaro av loesningsmedel
FI930165A (fi) Framstaellning av synnerligen aktiva tvaettmedelspartiklar
FI931355A (fi) Fasoeverfoeringsmedierat foerfarande foer framstaellning av glukamidtvaettmedel
FI931356A0 (fi) Foerbaettrat katalytiskt foerfarande foer framstaellning av glukamidtvaettmedel
FI925805A (fi) Framstaellning av kompositmaterial
FI925609A (fi) Foerfarande foer framstaellning av sykliska sulfater
FI931879A (fi) Framstaellning av en peroxosyra
FI923779A (fi) Foerbaettringar i tillverkningen av nylongarn
FI931534A0 (fi) Foerfarande foer foerbaettring av aktiveringen av hydrauliskt masugns slagg foer framstaellning av byggnadsmaterial
FI930034A0 (fi) Foerfarande foer framstaellning av avlaongt foeremaol
FI925544A (fi) Bensoesyraderivat foer behandling av leukotrienassocierade sjukdomar
FI925546A (fi) Amidkopplade pyridylbensoesyraderivat foer behandling av leukotrien-associerade sjukdomar
FI930013A0 (fi) Hormonderivat av bakre hypofysloben
FI930123A0 (fi) Foerfarande foer anvaendning av oxiderade lipoproteiner i virusartade infektioner
FI932901A0 (fi) Foerfarande foer framstaellning av alkalimonofluorfosfat
FI932198A0 (fi) Anordning foer skydd av kondensorroer
FI924154A (fi) Foerfarande foer framstaellning av penem-estrar
FI923795A (fi) Kretselement foer aostadkommande av en spaerrspaenning foer kopplinsdioder
FI88315C (fi) Foerfarande foer blekning av cellulosamassa

Legal Events

Date Code Title Description
FD Application lapsed